MPMahdia Parker

Mahdia Parker

*This is an algorithmically generated author record based on publicly available information.

Mahdia Parker has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development, Usability Testing, and Pilot Randomized Controlled Trial of WeCareToFeedDysphagia: A Web-Based Tool to Reduce Burden in Caregivers of Community-Dwelling Persons with Dementia and Oropharyngeal Dysphagia (Preprint)

    by Liron Sinvani, Michael A. Diefenbach, Alexandra Perrin, Samantha Gordon, Stefani Slotnick, Stephanie Groton, Nur-E Ferdous, Mahdia Parker, Huma Babar, Codruta Chiuzan, et al.

  • Open Access

    Development, Usability Testing, and Pilot Randomized Controlled Trial of WeCareToFeedDysphagia: A Web-Based Tool to Reduce Burden in Caregivers of Community-Dwelling Persons with Dementia and Oropharyngeal Dysphagia (Preprint)

    by Liron Sinvani, Michael A. Diefenbach, Alexandra Perrin, Samantha Gordon, Stefani Slotnick, Stephanie Groton, Nur-E Ferdous, Mahdia Parker, Huma Babar, Codruta Chiuzan, et al.

    BACKGROUND Oropharyngeal dysphagia (dysphagia) affects up to 86% of hospitalized patients with Alzheimer disease (AD) and AD-related dementias (AD/ADRD) and is a significant predictor of caregiver burden. Upon hospital discharge, caregivers face dramatic and persistent unmet dysphagia-related caregiving needs, yet no single comprehensive resource exists to address these needs. OBJECTIVE To develop (Aim 1), test the usability/acceptability (Aim 2), and conduct a pilot feasibility randomized controlled trial (RCT; Aim 3) of a web-based caregiver tool for feeding in dysphagia (WeCareToFeedDysphagia), designed to reduce burden in caregivers of community-dwelling persons with AD/ADRD and dysphagia. METHODS The study was conducted in three phases: (1) semi-structured interviews with 15 caregivers to develop website content; (2) usability/acceptability testing with 20 caregivers (all 20 completed Round 1) using the think-aloud method, discrete navigation tasks, and the System Usability Scale (SUS); and (3) a fully remote, two-arm pilot feasibility RCT (N=80) across 11 heterogeneous hospitals, randomizing caregivers to enhanced control (usual care + speech-language pathologist referral) or intervention (enhanced control + WeCareToFeedDysphagia), with assessments at baseline, 1-month, and 3-months post-hospital discharge. The primary objective of Aim 3 was to evaluate feasibility for a full-scale effectiveness RCT; clinical outcome analyses were exploratory. RESULTS Four primary qualitative themes emerged and consistent feedback was integrated: caregiver experience with dysphagia, dysphagia-related information gaps, hospital discharge deficiencies, and website content feedback. Among the 20 caregivers who completed usability testing, the average task success rate was 94% and the mean SUS score was 90.8 (SD=10.29), indicating high usability. In phase 3 (pilot feasibility RCT), we met 6 of 6 go/no-go feasibility milestones (i.e., consent rate, attrition, initial and follow-up text receipt, home page access, and tool engagement). The observed effect size (Cohen's d) for the exploratory primary clinical outcome (caregiver burden at 3 months) was -0.1 (95% CI: −0.6 to 0.4). Unadjusted, baseline-adjusted, and longitudinal analyses did not demonstrate statistically significant between-group differences in burden. A nominally significant difference was observed on the CarerQol-VAS happiness scale at 3 months (intervention 6.1 vs. control 4.9, mean difference:1.2, 95% CI: 0.1 to 2.3; P=.03); however, this finding was one of multiple exploratory comparisons without multiplicity adjustment and should be considered hypothesis-generating. CONCLUSIONS To our knowledge, WeCareToFeedDysphagia is the first stakeholder-informed, evidence-based, centralized web-based tool for caregivers of persons with AD/ADRD and dysphagia. It demonstrated high usability and acceptability. The pilot feasibility RCT demonstrated strong feasibility, meeting all pre-specified go/no-go milestones. These findings support transition to an NIH Stage IV (R33) full-scale effectiveness RCT (N=802). CLINICALTRIAL ClinicalTrials.gov NCT06557863; https://clinicaltrials.gov/study/NCT06557863